A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)
Latest Information Update: 20 May 2024
At a glance
- Drugs Emavusertib (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms LUCAS
- 24 Mar 2024 Status changed from recruiting to suspended.
- 08 Oct 2021 Status changed from not yet recruiting to recruiting.
- 12 May 2021 According to Curis media release, this study is expected to start recruitment in the second quarter of 2021.